Clinical Trials

The Sjögren’s Tool for Assessing Response, or STAR, a candidate composite efficacy endpoint for clinical trials, includes all disease features and has demonstrated sensitivity to change, according to researchers.

CHICAGO — Two speakers here reviewed what they believed were the top articles published in the Annals of Internal Medicine — research that reflects a diverse body of health issues and pharmacologic interventions.

Pfizer revealed plans to open sites in the U.S. for a phase 3 study evaluating an investigational mini-dystrophin gene therapy in ambulatory patients with Duchenne muscular dystrophy.

Measures of social determinants of health are substantially different in U.S. counties with diabetes clinical trial sites compared with counties with no trial sites, according to a research letter published in Diabetes Care.

Neuroscience company Cerevance announced the completion of its phase 2 clinical trial of CVN424, a once-daily oral compound developed for the treatment of Parkinson’s disease.

SEATTLE — Although advancements have been made in immune checkpoint inhibitors, tumors such as glioblastoma present a roadblock to successful therapy, according to a presenter at the 2022 American Academy of Neurology annual meeting.

The Research to Accelerate Cures and Equity Act led to an increase in required pediatric studies for recently approved cancer therapies within the first year of the act’s implementation, according to study results.

Cancer centers, advocacy groups and other organizations have ramped up efforts to reduce disparities across the cancer care continuum, according to presenters at the virtual National Comprehensive Cancer Network 2022 Annual Conference.

Clinical trials play an important role in developing and evaluating potential new cancer therapies.

The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.